Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00443196 · ClinicalTrials.gov registry record · Phase 2
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
A Phase 2 study of Ovarian Neoplasms and Adenocarcinoma, sponsored by Pierian Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT00443196: Completed Phase 2 study of Ovarian Neoplasms and Adenocarcinoma, sponsored by Pierian Biosciences.
NCT00443196 is a Phase 2 study of Ovarian Neoplasms and Adenocarcinoma that has completed, run by Pierian Biosciences. The registered enrollment target is 150 participants, below the 364-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00443196, a Phase 2 study of Ovarian Neoplasms and Adenocarcinoma, has completed, sponsored by Pierian Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
2.0 Study Objectives: 2.1 To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients for first-line treatment. 2.2 To evaluate the ability of the MiCK assay to guide chemotherapy of cancer patients in a third-line, refractory treatment setting (exclusive of anti-VEGF)
Conditions Studied
Interventions
- PROCEDURE MiCK Assay
Study Locations (1)
Georgia
- Southeastern Gynecologic Oncology - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
What the finished NCT00443196 record still lists
NCT00443196 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 364-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (59% lower).
The record links to 4 conditions, with Ovarian Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which MiCK Assay is the first listed.
NCT00443196 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT00443196 about?
NCT00443196 is a clinical study titled "Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas". 2.0 Study Objectives: 2.1 To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients for first-line treatment. 2.2 To evaluate the ability of the MiCK assay to guide chemotherapy of cancer patients in a third-line, refractory treatment setting (exclusive of ...
What is the current status of trial NCT00443196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2006-03. Estimated completion is 2010-09.
What conditions does trial NCT00443196 study?
This clinical trial studies the following conditions: Ovarian Neoplasms, Adenocarcinoma, Peritoneal Neoplasms, Fallopian Tube Neoplasms.
What interventions are being tested in trial NCT00443196?
The interventions under investigation include: MiCK Assay (PROCEDURE).
Who is sponsoring clinical trial NCT00443196?
This trial is sponsored by Pierian Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00443196 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00443196's enrollment target sits among peer trials
150 21st of 38 higher than 17 of 38 other Ovarian Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Trial of Vigil for Participants With Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
COMPLETED · Phase 2
-
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia